Developing strategies for liver fibrosis treatment

Expert Opinion on Investigational Drugs

Volumn 11, Issue 11, 2002, Pages 1575-1585

  Murphy, Frank ^a   Arthur, Michael ^a   Iredale, John ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Antifibrotic therapy; Hepatic stellate cell; Liver fibrosis

Indexed keywords

ACETYLCYSTEINE; ALPHA INTERFERON; ALPHA TOCOPHEROL; AMILORIDE; ANTIFIBROTIC AGENT; ANTIOXIDANT; AZATHIOPRINE; CARBON TETRACHLORIDE; COLCHICINE; CORTICOSTEROID; DILTIAZEM; DIMETHYLNITROSAMINE; FIBRILLAR COLLAGEN; GLYCYRRHIZIC ACID; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; MATRIX METALLOPROTEINASE; METHIONINE; NIFEDIPINE; PHOSPHATIDYLCHOLINE; RESVERATROL; RETINOL PALMITATE; RIBAVIRIN; S ADENOSYLMETHIONINE; SILYMARIN; THALIDOMIDE; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ALCOHOL LIVER CIRRHOSIS; ANTIINFLAMMATORY ACTIVITY; CELL ACTIVATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFICACY; DRUG TARGETING; HEMOCHROMATOSIS; HEPATITIS C; HUMAN; LIVER FIBROSIS; LIVER TRANSPLANTATION; MOUSE; NONHUMAN; OXIDATIVE STRESS; REVIEW; SIDE EFFECT; STELLATE CELL; TREATMENT OUTCOME; VIRUS HEPATITIS;

ANIMALS; HUMANS; LIVER CIRRHOSIS; TECHNOLOGY, PHARMACEUTICAL;

EID: 0036849481     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.11.11.1575     Document Type: Review

References (109)

1. FRIEDMAN SL: Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J. Biol. Chem. (2000) 275:2247-2250.
2. IREDALE JP, BENYON RC, PICKERING J et al.: Mechanisms of spontaneous resolution of rat liver fibrosis: hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J. Clin. Invest. (1998) 102:538-549.
3. ISSA R, WILLIAMS E, TRIM N et al.: Apoptosis of hepatic stellate cells: involvement in resolution of biliary fibrosis and regulation by soluble growth factors. Gut (2001) 48:548-557.
4. SCHIFF ER: Lamivudine for hepatitis B in clinical practice. J. Med. Virol. (2000) 61(3):386.
5. DAVIS GL, ESTEBAN-MUR R, RUSTGI V et al.: Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N. Engl. J. Med (1998) 339:1493-1499.
6. RAMM CA, CRAWFORD DHG, POWELL LW, WALKER NI, FLETCHER LM, HALLIDAY JW. Hepatic stellate cell activation in genetic haemochromatosis-Lobular distribution, effect of increasing hepatic iron and response to phlebotomy. J. Hepatol. (1997) 26:584-592.
7. SCHILSKY ML, SCHEINBERG IH, STERNLIEB I: Prognosis of Wilsonian chronic active hepatitis. Gastroenterology (1991) 100:762-767.
8. SHIRATORI Y, IMAZEKI F, MORIYAMA M et al.: Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann. Intern. Med. (2000) 132:517-524.
9. DUFOUR JF, DELELLIS R, KAPLAN MM: Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann. Int. Med. (1997) 127:981-985.
10. EMONARD H, GRIMAUD JA: Active and latent collagenase activity during reversal of hepatic fibrosis in murine schistosomiasis. Hepatology (1989) 10:77-83.
11. HAMMEL P, COUVELARD A, O'TOOLE D et al.: Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N. Engl. J. Med. (2001) 344:418-423.
12. POYNARD T, MCHUTCHISON J, DAVIS GL et al.: Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology (2000) 32:1131-1137.
13. POYNARD T, BEDOSSA P, OPOLON P: Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet (1997) 349:825-832.
14. MCCAUGHAN GW. GORRELL MD, BISHOP GA et al.: Molecular pathogenesis of liver disease: an approach to hepatic inflammation, cirrhosis and liver transplant tolerance. Immunol. Rev. (2000) 174:172-191.
15. CASINI A, CENI E, SALZANO R et al.: Neutrophil-derived superoxide anion induces lipid peroxidation and stimulates collagen synthesis in human hepatic stellate cells: role of nitric oxide. Hepatology (1997) 25:361-367.
16. NIKI T, SCHUPPAN D, DEBLESER PJ et al.: Dexamethasone alters messenger rna levels but not synthesis of collagens, fibronectin, or laminin by cultured rat fat-storing cells. Hepatology (1996) 23:1673-1681.
17. MATHURIN P, DUCHATELLE V, RAMOND MJ et al.: Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterology (1996) 110:1847-1853.
18. MITCHISON HC, PALMER JM, BASSENDINE MF, WATSON AJ, RECORD CO, JAMES OF: A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results. J. Hepatol. (1992) 15:336-344.
19. LINDOR KD, WIESNER RH, COLWELL LJ, STEINER B, BEAVER S, LARUSSO NF: The combination of prednisone and colchicine in patients with primary sclerosing cholangitis. Am. J. Gastroenterol. (1991) 86:57-61.
20. KERSHENOBICH D, VARGAS F, GARCIA-TSAO G, TAMAYO RP, GENT M, ROJKIND M: Colchicine in the treatment of cirrhosis of the liver. N. Engl. J. Med. (1988) 318:1709-1713.
21. POUPON RE, HUET PM, POUPON R, BONNAND AM, NHIEU JT, ZAFRANI ES: A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA-PBC Study Group. Hepatology (1996) 24:1098-1103.
22. PRESENT DH, RUTGEERTS P, TARGAN S et al.: Infliximab for the treatment of fistulas in patients with Crohn's disease. N. Engl. J. Med. (1999) 340:1398-1405.
23. JALAN R, WILLIAMS R, KASER A et al.: Clinical and cytokine response to anti-TNF antibody therapy in severe alcoholic hepatitis. Hepatology (2001) 34(4, Pt 2):A1077.
24. MURIEL P, PONCE S, GARCIA J: Thalidomide partially prevents CCL4-induced liver cirrhosis. Hepatology (2001) 34 (4, Pt. 2):A1378.
25. BRUCK R, SHIRIN H, HERSHKOVIZ R et al.: Analysis of Arg-Gly-Asp mimetics and soluble receptor of tumour necrosis factor as therapeutic modalities for concanavalin A induced hepatitis in mice. Gut (1997) 40:133-138.
26. MANCINI R, BENEDETTI A, JEZEQUEL AM: An interleukin-1 receptor antagonist decreases fibrosis induced by dimethylnitrosamine in rat liver. Virchows Arch. (1994) 424:25-31.
27. LOUIS H, VAN LAETHEM JL, WU W et al.: Interleukin-10 controls neutrophilic infiltration, hepatocyte proliferation, and liver fibrosis induced by carbon tetrachloride in mice. Hepatology (1998) 28:1607-1615.
28. NELSON DR, LAUWERS GY, LAU JY, DAVIS GL: Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology (2000) 118:655-660.
29. FRIEDMAN SL, ARTHUR MJP: Activation of cultured rat hepatic lipocytes by Kupffer cell conditioned medium. Direct enhancement of matrix synthesis and stimulation of cell proliferation via induction of platelet derived growth factor receptors. J. Clin. Invest. (1989) 84:1780-1785.
30. MAHER JJ: Leukocytes as modulators of stellate cell activation. Alcohol. Clin. Exp. Res. (1999) 23:917-921.
31. GRESSNER AM, LAHME B, BRENZEL A: Molecular dissection of the mitogenic effect of hepatocytes on cultured hepatic stellate cells. Hepatology (1995) 22:1507-1518.
32. REIMANN T, HEMPEL U, KRAUTWALD S et al.: Transforming growth factor-beta 1 induces activation of Ras, Raf- 1, MEK and MAPK in rat hepatic stellate cells. FEBS Lett. (1997) 403:57-60.
33. PINZANI M, MARRA F, CARLONI V: Signal transduction in hepatic stellate cells. Liver (1998) 18:2-13.
34. MARRA F, ARRIGHI MC, FAZI M et al.: Extracellular signal-regulated kinase activation differentially regulates platelet-derived growth factor's actions in hepatic stellate cells, and is induced by in vivo liver injury in the rat. Hepatology (1999) 30:951-958.
35. NIKI T, ROMBOUTS K, DE BLESER P et al.: A histone deacetylase inhibitor, trichostatin A, suppresses myofibroblastic differentiation of rat hepatic stellate cells in primary culture. Hepatology (1999) 29:858-867.
36. MIYAHARA T, SCHRUM L, RIPPE R et al.: Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J. Biol. Chem. (2000) 275:35715-35722.
37. MARRA F, EFSEN E, ROMANELLI RG et al.: Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology (2002) 119:466-478.
38. FRIEDMAN SL, YAMASAKI G, WONG L: Modulation of transforming growth factor beta receptors of rat lipocytes during the hepatic wound healing response. Enhanced binding and reduced gene expression accompany cellular activation in culture and in vivo. J. Biol. Chem. (1994) 269:10551-10558.
39. SATO M, KOJIMA N, MIURA M, IMAI K, SENOO H: Induction of cellular processes containing collagenase and retinoid by integrin-binding to interstitial collagen in hepatic stellate cell culture. Cell Biol. Int. (1998) 22:115-125.
40. MURPHY FR, ISSA R, ZHOU X et al: Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: Implications for reversibility of liver fibrosis. J. Biol. Chem. (2002) 277:11069-11076.
41. FAILLI P, RUOCCO C, DE FRANCO R et al.: The mitogenic effect of platelet-derived growth factor in human hepatic stellate cells requires calcium influx. Am. J. Physiol. (1995) 269:C1133-C1139.
42. DI SARIO A, BENDIA E, SVEGLIATI BG et al.: Intracellular pathways mediating Na+/H+ exchange activation by platelet-derived growth factor in rat hepatic stellate cells. Gastroenterology (1999) 116:1155-1166.
43. PAROLA M, LEONARDUZZI G, BIASI F et al.: Vitamin E dietary Suppl.ementation protects against carbon tetrachloride-induced chronic liver damage and cirrhosis. Hepatology (1992) 16:1014-1021.
44. DE LA MAZA MP, PETERMANN M, BUNOUT D, HIRSCH S: Effects of long-term vitamin E supplementation in alcoholic cirrhotics. J. Am. Coll. Nutr. (1995) 14:192-196.
45. PARK EJ, KO G, KIM J, SOHN DH: Antifibrotic effects of a polysaccharide extracted from Ganoderma lucidum, glycyrrhizin, and pentoxifylline in rats with cirrhosis induced by biliary obstruction. Biol. Pharm. Bull. (1997) 20:417-420.
46. GODICHAUD S, KRISA S, COURONNE B et al.: Deactivation of cultured human liver myofibroblasts by trans- resveratrol, a grapevine-derived polyphenol. Hepatology (2000) 31:922-931.
47. ALEYNIK SI, LEO MA, MA X, ALEYNIK MK, LIEBER CS: Polyenylphosphatidylcholine prevents carbon tetrachloride-induced lipid peroxidation while it attenuates liver fibrosis. J. Hepatol. (1997) 27:554-561.
48. MA X, ZHAO J, LIEBER CS: Polyenylphosphatidylcholine attenuates non-alcoholic hepatic fibrosis and accelerates its regression. J. Hepatol. (1996) 24:604-613.
49. PONIACHIK J, BARAONA E, ZHAO J, LIEBER CS: Dilinoleoylphosphatidylcholine decreases hepatic stellate cell activation. J. Lab. Clin. Med (1999) 133:342-348.
50. MIZOBUCHI Y, SHIMIZU I, YASUDA M, HORI H, SHONO M, ITO S: Retinyl palmitate reduces hepatic fibrosis in rats induced by dimethylnitrosamine or pig serum. J. Hepatol. (1998) 29:933-943.
51. MATO JM, CAMARA J, FERNANDEZ DP et al.: S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J. Hepatol. (1999) 30:1081-1089.
52. FERNANDEZ MI, TORRES MI, GIL A, RIOS A: Steatosis and collagen content in experimental liver cirrhosis are affected by dietary monounsaturated and polyunsaturated fatty acids. Scand. J. Gastroenterol. (1997) 32-350-356.
53. NANJI AA, ZAKIM D, RAHEMTULLA A et al.: Dietary saturated fatty acids down-regulate cyclooxygenase-2 and tumor necrosis factor alfa and reverse fibrosis in alcohol-induced liver disease in the rat. Hepatology (1997) 26:1538-1545.
54. BOIGK G, STROEDTER L, HERBST H, WALDSCHMIDT J, RIECKEN EO, SCHUPPAN D: Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology (1997) 26:643-649.
55. PARES A, PLANAS R, TORRES M et al.: Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. J. Hepatol. (1998) 28:615-621.
56. KATAOKA S, ALAM R, DASH PK, YATSU FM: Inhibition of PDGF-mediated proliferation of vascular smooth muscle cells by calcium antagonists. Stroke (1997) 28:364-369.
57. ZHU J, WU J, FRIZELL E et al.: Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis. Gastroenterology (1999) 117:1198-1204.
58. MARRA F, GRANDALIANO G, VALENTE AJ, ABBOUD HE: Thrombin stimulates proliferation of liver fat-storing cells and expression of monocyte chemotactic protein-1: potential role in liver injury. Hepatology (1995) 22:780-787.
59. BATALLER R, GINES P, NICOLAS JM et al.: Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology (2000) 118:1149-1156.
60. JONSSON JR, CLOUSTON AD, ANDO Y et al: Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology (2001) 121:148-155.
61. FAILLI P, DEFRANCO RM, CALIGIURI A et al.: Nitrovasodilators inhibit platelet-derived growth factor-induced proliferation and migration of activated human hepatic stellate cells. Gastroenterology (2000) 119:479-492.
62. UEKI T, KANEDA Y, TSUTSUI H et al: Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat. Med. (1999) 5:226-230.
63. WINDMEIER C, GRESSNER AM: Pharmacological aspects of pentoxifylline with emphasis on its inhibitory actions on hepatic fibrogenesis. Gen. Pharmacol. (1997) 29:181-196.
64. REIF S, WEIS B, AEED H et al: The Ras antagonist, farnesylthiosalicylic acid (FTS), inhibits experimentally-induced liver cirrhosis in rats.J Hepatol. (1999) 31:1053-1061.
65. WANG YQ, IKEDA K, IKEBE T et al: Inhibition of hepatic stellate cell proliferation and activation by the semisynthetic analogue of fumagillin TNP-470 in rats. Hepatology (2000) 32:980-989.
66. BRUCK R, HERSHKOVIZ R, LIDER O et al.: Inhibition of experimentally-induced liver cirrhosis in rats by a nonpeptidic mimetic of the extracellular matrix-associated Arg-Gly-Asp epitope. J. Hepatol. (1996) 24:731-738.
67. LANG A, SCHOONHOVEN R, TUVIA S, BRENNER DA, RIPPE RA: Nuclear factor κB in proliferation, activation, and apoptosis in rat hepatic stellate cells. J. Hepatol. (2000) 33:49-58.
68. WRIGHT MC, ISSA R, SMART DE et al.: Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. Gastroenterology (2001) 121:685-698.
69. SAILE B, KNITTEL T, MATTHES N, SCHOTT P, RAMADORI G: CD95/CD95L-mediated apoptosis of the hepatic stellate cell. Am. J. Pathol. (1997) 151:1265-1272.
70. TRIM N, MORGAN S, EVANS M et al.: Hepatic stellate cells express the low affinity nerve growth factor receptor p75 and undergo apoptosis in response to nerve growth factor stimulation. Am. J. Pathol. (2000) 156:1235-1243.
71. LI L, TAO J, DAVAILLE J et al: 15-deoxy-Delta 12,14-prostaglandin J2 induces apoptosis of human hepatic myofibroblasts. A pathway involving oxidative stress independently of peroxisome-proliferator-activated receptors. J. Biol. Chem. (2001) 276:38152-38158.
72. FISCHER R, SCHMITT M, BODE JG, HAUSSINGER D: Expression of the peripheral-type benzodiazepine receptor and apoptosis induction in hepatic stellate cells. Gastroenterology (2001) 120:1212-1226.
73. SAKAIDA I, UCHIDA K, HIRONAKA K, OKITA K: Prolyl 4-hydroxylase inhibitor (HOE 077) prevents TIMP-1 gene expression in rat liver fibrosis. J Gastroenterol. (1999) 34:376-377.
74. WANG YJ, WANG SS, BICKEL M, GUENZLER V, GERL M, BISSELL DM: Two novel antifibrotics, HOE 077 and Safironil, modulate stellate cell activation in rat liver injury: differential effects in males and females. Am. J. Pathol. (1998) 152:279-287.
75. SAKAIDA I, MATSUMURA Y, KUBOTA M, KAYANO K, TAKENAKA K, OKITA K: The prolyl 4-hydroxylase inhibitor hoe 077 prevents activation of ito cells, reducing procollagen gene expression in rat liver fibrosis induced by choline-deficient l-amino acid-defined diet. Hepatology (1996) 23:755-763.
76. MATSUMURA Y, SAKAIDA I, UCHIDA K, KIMURA T, ISHIHARA T, OKITA K: Prolyl 4-hydroxylase inhibitor (HOE 077) inhibits pig serum-induced rat liver fibrosis by preventing stellate cell activation. J. Hepatol, (1997) 27:185-192.
77. BICKEL M, BARINGHAUS KH, GERL M et al: Selective inhibition of hepatic collagen accumulation in experimental liver fibrosis in rats by a new prolyl 4-hydroxylase inhibitor. Hepatology (1998) 28:404-411.
78. MATSUSAKA T, KATORI H, INAGAMI T, FOGO A, ICHIKAWA I: Communication between myocytes and fibroblasts in cardiac remodeling in angiotensin chimeric mice. J. Clin. Invest. (1999) 103:1451-1458.
79. KLAHR S, MORRISSEY JJ: The role of vasoactive compounds, growth factors and cytokines in the progression of renal disease. Kidney Int. Suppl. (2000) 75:S7-S14.
80. CAMINO A, GONZALEZ P, PALACIOS L, FERRANDO J, LAGUENS R, SILVA M: Enalapril attenuates liver fibrogenesis in an animal model. Hepatology (2001) 34(4, Pt. 2):A936.
81. PINZANI M, MILANI S, DEFRANCO R et al.: Endothelin-1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells. Gastroenterology (1996) 110:534-548.
82. CHO JJ, HOCHER B, HERBST H et al.: An oral endothelin-A receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosis. Gastroenterology (2000) 118:1169-1178.
83. PINES M, KNOPOV V, GENINA O, LAVELIN I, NAGLER A: Halofuginone, a specific inhibitor of collagen Type I synthesis, prevents dimethylnitrosamine-induced liver cirrhosis. J. Hepatol. (1997) 27:391-398.
84. ROCKEY DC, MAHER JJ, JARNAGIN WR, GABBIANI G, FRIEDMAN SL: Inhibition of rat hepatic lipocyte activation in culture by interferon-gamma. Hepatology (1992) 16:776-784.
85. BARONI GS, D'AMBROSIO L, CURTO P et al.: Interferon gamma decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis. Hepatology (1996) 23:1189-1199.
86. MALLAT A, PREAUX AM, BLAZEJEWSKI S, ROSENBAUM J, DHUMEAUX D, MAVIER P: Interferon alfa and gamma inhibit proliferation and collagen synthesis of human ito cells in culture. Hepatology (1995) 21:1003-1010.
87. SHI Z, WAKIL AE, ROCKEY DC: Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses. Proc. Natl. Acad. Sci. USA (1997) 94:10663-10668.
88. FRIEDMAN SL, YAMASAKI G: Characterisation of TGF-beta receptors in cultured rat lipocytes; enhanced receptor expression accompanies cellular activation. Hepatology (1991) 14:113A.
89. HELDIN CH, MIYAZONO K, TEN DIJKE P: TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature (1997) 390:465-471.
90. GUNTHER M, HAUBECK HD, VANDELEUR E et al.: Transforming Growth Factor beta 1 Regulates Tissue Inhibitor of Metalloproteinases-1 Expression in Differentiated Human Articular Chondrocytes. Arthritis Rheum. (1994) 37:395-405.
91. OKUNO M, MORIWAKI H, MUTO Y, KOJIMA S: Protease inhibitors suppress TGF-beta generation by hepatic stellate cells. J. Hepatol. (1998) 29:1031-1032.
92. GEORGE J, ROULOT D, KOTELIANSKY VE, BISSELL MD: Inhibition of rat hepatic fibrogenesis by a soluble TGF beta Type II receptor. Hepatology (1998) 28:312A.
93. QI Z, ATSUCHI N, OOSHIMA A, TAKESHITA A, UENO H: Blockade of type beta transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat. Proc. Natl. Acad. Sci. USA (1999) 96:2345-2349.
94. STEFANOVIC B, LINDQUIST J, BRENNER DA: The 5' stem-loop regulates expression of collagen alphal (I) mRNA in mouse fibroblasts cultured in a three-dimensional matrix. NucleicAcids. Res. (2000) 28: 641-647.
95. STEFANOVIC B, HELLERBRAND C, HOLCIK M, BRIENDL M, LIEBRABER SA, BRENNER DA: Posttranscriptional regulation of collagen alpha I (I) mRNA in hepatic stellate cells. Mol. Cell. Biol. (1997) 17:5201-5209.
96. SALGADO S, GARCIA J, VERA J et al.: Liver cirrhosis is reverted by urokinase-type plasminogen activator gene therapy. Mol. Ther. (2000) 2:545-551.
97. NISHIO T, IIMURO Y. SHINKURA N et al.: Overexpression of matrix metalloproteinase-1 in the rat liver for modulation of hepatic extracellular matrix. Hepatology (1998) 28-A1426.
98. NIE QH, CHENG YQ, XIE YM, ZHOU YX, CAO YZ: Inhibiting effect of antisense oligonucleotides phosphorthinate on gene expression of TIMP-1 in rat liver fibrosis. World J. Gastroenterol. (2001) 7:363-369.
99. WANG J, JIANG W, YANG C, WANG Y, HE B: Effects of antisense tissue inhibitor of metalloproteinase-1 expressing plasmid on pig serum induced rat liver fibrosis. Gastroenerology (2002):M839.
100. GIMENEZ A, CABALLERIA J, PARES A et al.: Influence of dietary zinc on hepatic collagen and prolyl hydroxylase activity in alcoholic rats. Hepatology (1992) 16:815-819.
101. GIMENEZ A, PARES A, ALIE S et al.: Fibrogenic and collagenolytic activity in carbon- tetrachloride- injured rats: Beneficial effects of zinc administration. J. Hepatol. (1994) 21:292-298.
102. BELJAARS L, MOLEMA G, WEERT B et al.: Albumin modified with mannose 6-phosphate: A potential carrier for selective delivery of antifibrotic drugs to rat and human hepatic stellate cells. Hepatology (1999) 29:1486-1493.
103. BELJAARS L, MOLEMA G, SCHUPPAN D et al.: Successful targeting to rat hepatic stellate cells using albumin modified with cyclic peptides that recognize the collagen Type VI receptor. J. Biol. Chem. (2000) 275:12743-12751.
104. GUECHOT J, POUPON RE, POUPON R: Serum hyaluronan as a marker of liver fibrosis. J. Hepatol. (1995) 22:103-106.
105. SUOU T, HOSHO K, KISHIMOTO Y, HORIE Y, KAWASAKI H: Long-term decrease in serum N-terminal propetide of Type III procollagen in patients with chronic hepatitis C treated with interferon alfa. Hepatology (1995) 22:426-431.
106. KASAHARA A, HAYASHI N, MOCHIZUKI K et al : Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C - Relationship to interferon response. J. Hepatol. (1997) 26:574-583.
107. UENO T, TAMAKI S, SUGAWARA H et al.: Significance of serum tissue inhibitor of metalloproteinases-1 in various liver diseases. J. Hepatol. (1996) 24:177-184.
108. TSUTSUMI M, TAKASE S, URASHIMA S, UESHIMA Y, KAWAHARA H, TAKADA A. Serum markers for hepatic fibrosis in alcoholic liver disease: Which is the best marker, Type III procollagen, Type IV collagen, laminin, tissue inhibitor of metalloproteinase, or prolyl hydroxylase? Alcohol. Clin. Exp. Res. (1996) 20:1512-1517.
109. ROSENBERG WM, BURT A, BECKA M et al.: Automated assays of serum markers of liver fibrosis predict histological hepatic fibrosis. Hepatology (2000) 32:A84.